Premium
Clinical and Economic Effectiveness of an Inpatient Anticoagulation Service
Author(s) -
Mamdani Muhammad M.,
Racine Eric,
McCreadie Scott,
Zimmerman Chris,
O'Sullivan Tami L.,
Jensen Gail,
Ragatzki Paul,
Stevenson James G.
Publication year - 1999
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.19.13.1064.31591
Subject(s) - medicine , partial thromboplastin time , warfarin , pharmacist , clinical endpoint , managed care , emergency medicine , primary care , end point , clinical pharmacy , prospective cohort study , intensive care medicine , pharmacy , randomized controlled trial , family medicine , health care , atrial fibrillation , coagulation , geometry , mathematics , economics , economic growth
We conducted a prospective cohort study to evaluate clinical and economic end points achieved by a pharmacist‐managed anticoagulation service compared with usual care (50 patients/group). The primary therapeutic end point was the time between starting heparin therapy and surpassing the activated partial thromboplastin time therapeutic threshold. The primary economic end point was the direct variable cost of hospitalization from admission to discharge. No significant differences between groups were noted for the primary therapeutic end point. Total hospital costs were significantly lower for patients receiving pharmacist‐managed care than for those receiving usual care ($1594 and $2014, respectively, 1997 dollars, p=0.04). Earlier start of warfarin (p=0.05) and shorter hospital stay (5 and 7 days, p=0.05) were associated with the pharmacist‐managed group.